EU Approved Cenrifki for a Difficult-to-Treat Form of Progressive MS
Sanofi’s Cenrifki/tolebrutinib was approved in the EU for secondary progressive multiple sclerosis without recent relapses, where disability can worsen even without flare-ups.
- Published
- Jun 24, 2026
- Last updated
- Jun 24, 2026
- Last reviewed
- Jun 24, 2026
- Status
- Confirmed
- Primary source
- Sanofi
- Verification
- Corroborated reporting
Rapid orientation
The 5-second read
- What happened
- The EU approved Cenrifki for adults with secondary progressive MS without recent relapses, a difficult-to-treat stage marked by worsening disability.
- Why it matters
- Disability can progress in MS even without obvious relapses.
- Status
- Confirmed
- Overclaim risk
- Medium
- Primary source
- Sanofi (Company)
- Next thing to watch
- Post-approval safety monitoring, real-world disability outcomes, and whether U.S. regulators reach a similar conclusion.
Claim Check
ConfirmedThe European Commission approved Cenrifki, also known as tolebrutinib, for adults with secondary progressive multiple sclerosis without relapses in the last two years.
Safe framing
The EU approved Cenrifki for adults with secondary progressive MS without recent relapses, a difficult-to-treat stage marked by worsening disability.
What happened
The European Commission has approved Cenrifki, also known as tolebrutinib, for adults with secondary progressive multiple sclerosis who have not had relapses in the previous two years. This is a stage where disability can continue to worsen without obvious flare-ups.
That distinction matters because many MS treatments are discussed in terms of relapse reduction. Progressive disability is a different target and has left some patients with fewer options.
The approval is European, indication-specific, and does not mean the drug reverses disability or cures MS. Benefit-risk communication and any required monitoring remain part of the story.
Why it matters
- Disability can progress in MS even without obvious relapses.
- A therapy aimed at progression could matter for a group with limited options.
- The EU decision makes careful benefit-risk communication especially important.
What not to overclaim
- Cenrifki is not a cure for MS.
- It is not approved for every person with MS.
- The approval does not mean the drug reverses disability.
- European approval does not imply U.S. approval.
Signal context
Context
- Primary topic
- Multiple Sclerosis
- Source date
- Jun 23, 2026
- Source stack
- 2 sources
- Current status
- Confirmed
Evidence trail
Source stack
- PrimaryCompanyJun 23, 2026Sanofi: Cenrifki approved in the EU for secondary progressive multiple sclerosis without relapses
- IndependentTrade newsJun 24, 2026Wall Street Journal: Sanofi Multiple Sclerosis Drug Gets EU Approval
Keep following the signal